Stock comparison
CONMED
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CNMD
CONMED
Market cap
$1.12B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CNMD | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 45D | 75B | IDXX |
| Benjamin Graham | 36D | 80A | IDXX |
| Philip Fisher | 34F | 75B | IDXX |
| Peter Lynch | 21F | 71B | IDXX |
| Joel Greenblatt | 24F | 83C | IDXX |
| Charlie Munger | 41D | 87A | IDXX |
| Terry Smith | 36D | 84A | IDXX |
Side-by-side metrics
| Metric | CNMD | IDXX |
|---|---|---|
| Market cap | $1.12B | $44.12B |
| P/E (TTM) | 19.6x | 39.0x |
| EV/EBIT | 13.4x | 31.6x |
| ROIC (TTM) | 5.08% | 40.66% |
| Gross margin | 53.58% | 62.05% |
| Net margin | 4.0% | 24.63% |
| Revenue CAGR 5y | 7.99% | 7.56% |
| EPS CAGR 5y | -8.2% | 10.79% |
| Debt / Equity | 0.8x | 0.7x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CNMD leads on
- Dividend yield1.14%vs 0.0%+100%
- EV/EBIT13.4xvs 31.6x+58%
- P/E (TTM)19.6xvs 39.0x+50%
- Revenue CAGR 5y7.99%vs 7.56%+5%
IDXX leads on
- EPS CAGR 5y10.79%vs -8.2%+176%
- Market cap$44.12Bvs $1.12B+97%
- ROIC (TTM)40.66%vs 5.08%+87%
- Net margin24.63%vs 4.0%+84%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.